Quick Search:

is currently disabled due to reindexing of the ZORA database. Please use Advanced Search.
uzh logo
Browse by:

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-43017

Stupp, R; Weller, M (2010). 2010: neuro-oncology is moving! Current Opinion in Neurology, 23(6):553-555.

[img] PDF (Verlags-PDF) - Registered users only
Accepted Version


The first randomized phase III trial in patients with primary central nervous system lymphoma was reported for the first time at the 2010 annual meeting of the American Society of Clinical Oncology, and concluded that the omission of whole brain radiotherapy from first-line treatment does not compromise survival. Two randomized trials investigated tailored treatment strategies for elderly patients with glioma and reached opposite conclusions. Novel treatment approaches in recurrent glioblastoma with alternating tumour treatment fields (NovoTTF), or antiangiogenic agents (cilengitide and bevacizumab) have been reported and updated. The role of vascular endothelial growth factor-inhibiting strategies in the management of recurrent glioma remains unclear and controversial.

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
DDC:610 Medicine & health
Deposited On:26 Jan 2011 19:31
Last Modified:27 Nov 2013 22:37
Publisher:Lippincott Wiliams & Wilkins
Additional Information:This a non-final version of an article published in final form in Current Opinion in Neurology, 23(6):553-555. DOI: 10.1097/WCO.0b013e3283407eed
Publisher DOI:10.1097/WCO.0b013e3283407eed
PubMed ID:21051962
Citations:Web of Science®. Times Cited: 2
Google Scholar™
Scopus®. Citation Count: 3

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page